



2020

Financial Status as of February 15, 2021 (with unaudited preliminary 2020 financials)

Note

This Financial Status with preliminary unaudited financial figures as of December 31, 2020, has been prepared exclusively in view of the Bondholders' Meeting of Santhera Pharmaceuticals Holding of March 8, 2021.

The Company expects to publish its 2020 Annual Report, with audited financial statements, on April 27, 2021.



Santhera Pharmaceuticals Holding AG
Pratteln, Switzerland

Financial Status according to art. 1175 of the Swiss Code of Obligations

February 15, 2021

*Important note: The financial figures for the year ended and as of December 31, 2020, and for any periods and as of any dates after December 31, 2020, presented in this financial status (the **Financial Status**) have been prepared exclusively in view of the upcoming bondholders' meeting of Santhera Pharmaceuticals Holding AG, as required by art. 1175 of the Swiss Code of Obligations. This Financial Status is not a financial statement in the sense of art. 958 et seq. of the Swiss Code of Obligations or under any applicable financial reporting standards. The financial figures for the year ended and as of December 31, 2020, and for any periods and as of any dates after December 31, 2020, presented in this Financial Status are preliminary and have not been and will not be audited. The Company expects to publish its 2020 annual report, which will include its audited consolidated financial statements and its audited statutory financial statements for the year ended and as of December 31, 2020, later this year (together, the **2020 Financial Statements**). The financial figures in this Financial Status for the year ended and as of December 31, 2020, may differ from those that will be set forth in the 2020 Financial Statements.*

Income Statement

<i>Abbreviated Statements</i>		Consolidated		Statutory	
		(IFRS)		(Swiss Code of Obligations)	
<u>Year ended December 31</u>		<u>2020</u>	<u>2019</u>	<u>2020</u>	<u>2019</u>
<i>CHF thousands</i>	<u>Note</u>	<u>Unaudited</u>	<u>Audited</u>	<u>Unaudited</u>	<u>Audited</u>
Net sales	1	13'411	29'006	-	-
Revenue from out-licensing transactions	1	1'597	46'370	-	-
Income from shareholdings		-	-	537	1'217
Total revenue		15'008	75'376	537	1'217
Cost of goods sold		(10'431)	(5'450)	-	-
Other operating income		799	284	-	45
Operating expenses		(61'983)	(80'652)	(3'742)	(5'516)
Operating result		(56'607)	(10'442)	(3'205)	(4'254)
Net financial income / (expense)		(14'427)	(7'952)	(4'514)	(4'501)
Result before taxes		(71'034)	(18'394)	(7'719)	(8'755)
Income taxes		(203)	(579)	-	-
Net result		(71'237)	(18'973)	(7'719)	(8'755)

Notes: 1 In August 2019 Raxone was out-licensed to Chiesi Farmaceutici S.p.A/ ("Chiesi") for the treatment of Leber's hereditary optic neuropathy in certain markets.

Balance Sheet

<i>Abbreviated Statements</i>		Consolidated (IFRS)		Statutory (Swiss Code of Obligations)	
As of December 31		2020	2019	2020	2019
<i>CHF thousands</i>	<u>Note</u>	<u>Unaudited</u>	<u>Audited</u>	<u>Unaudited</u>	<u>Audited</u>
Assets					
Tangible assets		1'902	5'604	-	-
Intangible assets		67'673	58'479	-	-
Loans to & investments in shareholdings	1	-	-	142'870	118'964
Other long-term assets		1'389	1'713		
Noncurrent assets		70'964	65'796	142'870	118'964
Inventories		481	6'859	-	-
Receivables & prepayments		4'831	9'538	270	122
Restricted cash		-	1'500	-	1'500
Cash and cash-equivalents		12'411	31'358	6'625	7'658
Current assets		17'723	49'255	6'895	9'280
Total assets		88'687	115'051	149'765	128'244
Liabilities & equity					
Trade and other payables		5'715	9'532	270	293
Accrued expenses & provisions		14'010	11'427	1'955	1'973
Accrued income taxes		60	395	-	-
Contract & leasing liabilities		1'895	2'610	-	-
Exchangeable notes & financing		10'720	-	10'000	-
Other accounts payable to shareholdings		-	-	-	68
Current liabilities		32'400	23'964	12'225	2'334
Convertible bonds		57'875	56'154	60'000	60'000
Contract & leasing liabilities		1'927	3'953	-	-
Derivative financial instruments		-	617	-	-
Pension liabilities		6'170	9'116	-	-
Noncurrent liabilities		65'972	69'840	60'000	60'000
Total liabilities		98'372	93'804	72'225	62'334
Share capital		19'430	11'165	19'430	11'165
Capital reserves & share premium		480'254	448'084	15'792	9'873
Treasury shares		(1'580)	(745)	(1'580)	(746)
Other reserves & currency translation		(3'312)	(4'017)	83'994	77'995
Retained earnings		(504'477)	(433'240)	(40'096)	(32'377)
Total equity		(9'685)	21'247	77'540	65'910
Total liabilities & equity		88'687	115'051	149'765	128'244

Notes: 1. Includes loans to group companies to further develop drug compounds to support vamorolone and lonodelestat (both of which are in development) and Raxone (outlicensed to Chiesi in 2019 and marketed in Europe).

Balance Sheet – Update as of January 31, 2021

<i>Unaudited Abbreviated Statements</i>	Consolidated (IFRS)			Statutory (Swiss Code of Obligations)		
	<u>Dec. 31, 2020</u>	<u>Movement</u>	<u>Jan. 31, 2021</u>	<u>Dec. 31, 2020</u>	<u>Movement</u>	<u>Jan. 31, 2021</u>
<i>CHF thousands</i>						
Assets						
Noncurrent assets	70'964	(254)	70'710	142'870	501	143'371
Inventories	481	(56)	425	-	-	-
Receivables & prepayments	4'831	531	5'362	270	(35)	235
Cash and cash-equivalents	12'411	(2'761)	9'650	6'625	(105)	6'520
Current assets	17'723	(2'286)	15'437	6'895	(140)	6'755
Total assets	88'687	(2'540)	86'147	149'765	361	150'126
Liabilities & equity						
Trade payables	5'715	(2'122)	3'593	270	(179)	91
Accrued expenses & provisions	14'010	(1'006)	13'004	1'955	249	2'204
Accrued income taxes	60	-	60	-	-	-
Contract & leasing liabilities	1'895	(60)	1'835	-	-	-
Exchangeable notes & financing	10'720	280	11'000	10'000	-	10'000
Current liabilities	32'400	(2'908)	29'492	12'225	70	12'295
Convertible bonds	57'875	148	58'023	60'000	-	60'000
Liabilities	1'927	(170)	1'757	-	-	-
Pension liabilities	6'170	-	6'170	-	-	-
Noncurrent liabilities	65'972	(22)	65'950	60'000	-	60'000
Total liabilities	98'372	(2'930)	95'442	72'225	70	72'295
Total equity	(9'685)	390	(9'295)	77'540	291	77'831
Total liabilities & equity	88'687	(2'540)	86'147	149'765	361	150'126

Consolidated Cash Position (TCHF)

Unaudited

Date	Balance	Movement	Bond interest
December 31, 2020	12'411		
January 31, 2021	9'650	(2'761)	
February 15, 2021 (projected)	8'361	(1'289)	
Convertible Bond interest payment (Feb 17, 2021)			(1'500)
Projected cash balance after Convertible Bond interest payment	6'861		